Since 2015, the FDA’s main drug review office has approved more than ten dozen new cancer drugs. Learn how cancer research is advancing and how it’s changing the industry in the process in
this Trendline.
The investment bank says funding was down 57% last month, to $2.7 billion, and argues the new administration’s FDA restructuring, NIH cuts and drug pricing rules are “exacerbating” the decline.
The company is one of the first to receive a “platform technology designation,” which could speed the review of certain gene therapy applications it later brings to the regulator.
The deal, which could be worth up to $870 million overall, will give Lilly access to a delivery technology that may help extend the durability of up to four of its weight-loss medicines.
Catalent FlexDirect® allows clinical supplies to be delivered directly to patients’ homes, minimizing or removing the need for clinical site visits. Discover more about DTP.
Breast cancer study results impressed at this year’s meeting, but raised new questions. Doctors also wrestled with how best to use new bispecific antibodies, and expressed concern about looming cuts to science funding.
The oncology giant will pay $1.5 billion to co-develop a BioNTech drug that targets the proteins PD-L1 and VEGF, following Merck and Pfizer into what’s become a competitive development race.
Tomorrow’s most effective treatments will likely combine conventional medications and digital apps. Learn how pharma leaders are already improving access, adherence and engagement in this playbook.
